November 8: Company established, settling in the Zhangjiang Science City HiMed Xingxi Medical Innovation Incubation Platform.
Lingang headquarters office building renovation commenced; GMP Grade 10,000 clean workshop under construction.
V-Mixtent® Venous Stent System design finalized.
V-Sealing® Venous Closure System market research initiated.
Received multi-million-yuan angel investment from Shanghai Fucheng Qingyun Investment Center (Limited Partnership).
Company fully relocated to Lingang headquarters.
V-Mixtent® Venous Stent System completed animal studies and initiated clinical trials.
V-Sealing® Venous Closure System R&D initiated.
Awarded Shanghai High-Tech Enterprise status.
Received investment from Shanghai Haimai Dexingxi Venture Capital Partnership (Limited Partnership).
Won the Gold Award at the 2020 Nanxiang Precision Medicine International Innovation and Entrepreneurship Competition Grand Finals.
V-Mixtent® Venous Stent System clinical trial enrollment completed ahead of schedule; preparation for registration commenced.
V-BDC Peripheral Balloon Dilatation Catheter market research initiated.
Received multi-million-yuan project funding from Lingang New Area's High-Tech Industry and Science & Technology Innovation Special Project.
Recognized as one of Fengxian District's "Three 100s" Enterprises.
Won First Prize at the 4th (2021) China Medical Device Innovation and Entrepreneurship Competition (High-Value Consumables and Implantable/Interventional Devices Category – Semifinals).
Won First Prize at the 4th (2021) China Medical Device Innovation and Entrepreneurship Competition (High-Value Consumables and Implantable/Interventional Devices Category – Finals).
Received the "Lingang Park Rising Star" title.
Received investment from Shaoxing Keqiao Huayu Jiuzhixinfei Equity Investment Partnership (Limited Partnership).
V-CLOFF® Deep Vein Thrombus Removal System project initiated.
EnDojet® Syringe Auxiliary Propulsion Pump project initiated, marking the completion of the three major R&D platforms.
V-Sealing® Venous Closure System completed animal studies and clinical trials. Received the 2022 Outstanding Innovation Case Award from VCBeat (Dongmai Wang).
Received the 2022 Outstanding Innovation Case Award from VCBeat (Dongmai Wang).
Obtained ISO 13485 Quality Management System Certification.
Company General Manager Mr. Wang Shengqiang was selected for the 2022 "Shanghai Industry Youth Top Talent" High-Level Talent Training Program: Industry Leading Talent.
Completed nearly RMB 100 million Series A financing, led by Mifang Capital, with participation from Zeyue Capital and Laishi Capital, and continued support from existing shareholders Fucheng Capital and Jiuzhixinfei Capital.
V-HaloSnare® Peripheral Vascular Snare obtained NMPA registration certificate.
EnDojet® Syringe Auxiliary Propulsion Pump submitted for registration application.
Selected as a 2023 Shanghai High-Value Patent Cultivation Center project undertaking unit.
Obtained Intellectual Property Management System Certification.
Obtained Medical Device Production License from Shanghai Medical Products Administration.
Company General Manager Mr. Wang Shengqiang was selected for the 2023 Oriental Talents Program Top-Tier Project.
Received Excellence Award in the Biopharmaceutical Unit of the Lingang Cup 10th Shanghai Youth Innovation and Entrepreneurship Competition.
Received Lingang Group Park Rising Star award.
V-Mixtent® Venous Stent System obtained NMPA registration certificate.
EnDojet® Syringe Auxiliary Propulsion Pump obtained NMPA registration certificate.
"Shanghai Endovascular Medical Technology Co., Ltd. High-End Implantable/Interventional Device Manufacturing Plant" was recognized as a Lingang New Area Smart Factory Enterprise.
V-Mixtent® Venous Stent System was successfully selected for the 5th National Centralized High-Value Medical Consumables Procurement list.
Received multi-million-yuan equity financing from Guolian Guigu Venture Capital.
V-Mixtent® Venous Stent System obtained registration certificates for Malaysia and Indonesia.
V-HaloSnare® Peripheral Vascular Snare obtained registration certificates for Malaysia and Indonesia.
First overseas implantation of V-Mixtent® Venous Stent System completed, marking the official launch of overseas market sales.
Recognized as a 2025 Shanghai Specialized and Sophisticated SME (Shanghai "Specialized, Refined, Distinctive, and Innovative" SME).
V-SAILING® Peripheral Venous Thrombectomy Stent System obtained NMPA registration certificate.
V-BALLEX® Peripheral Balloon Dilatation Catheter obtained NMPA registration certificate.
V-BALLEX® Peripheral Balloon Dilatation Catheter obtained CE registration certificate.
V-HaloSnare® Peripheral Vascular Snare obtained CE registration certificate.
"Benefit the world through wisdom, create the future with innovation."
To become a renowned medical technology company with unique innovations in the field of peripheral vascular diseases, recognized both domestically and internationally.
"Grace the multitude, honor through reputation."
Dedicated to medical innovation that serves the public;
Committed to collective endeavor that earns customer recognition.
Enrich public welfare with a benevolent heart, and set industry benchmarks with utmost sincerity.
Guard the dignity of life with masterful craftsmanship, and scale the peaks of medicine with unwavering perseverance.
Embrace Diversity, Integrate All
Forge Together in Unity, Harmonious in Difference
Unite Knowledge and Action, Value Every Second
switchboard：+86 21 33658866
Scan to follow the official account
